Platelets, Prostanoids and Percutaneous Transluminal Coronary Angioplasty

  • H. Riess
Conference paper


The high frequency of restenosis is one limitation on the benefit of percutaneous transluminal coronary angioplasty (PTCA). As platelet behaviour is thought to be important in the pathogenesis of vasospasm, early coronary artery occlusion and restenosis, antiplatelet therapy is initiated in most patients undergoing PTCA, despite the fact that clear evidence for the beneficial effect of this therapeutic strategy is still lacking.


Bleeding Time Arachidonic Acid Metabolism Arachidonic Acid Metabolite Arteriosclerosis Obliterans Thromboxane Synthetase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Block PC, Fallon JT, Elmer D (1980) Experimental angioplasty: lessons from the laboratory. AJR 135: 907PubMedGoogle Scholar
  2. 2.
    Block PC, Baughman KL, Pasternak RC, Fallon JT (1980) Transluminal angioplasty: correlation of morphologic and angiographic findings in an experimental model. Circulation 61: 778PubMedGoogle Scholar
  3. 3.
    Gerlach E, Nees S, Becker BF (1985) The vascular endothelium: a survey of some newly evolving biochemical and physiological features. Basic Res Cardiol 80: 457CrossRefGoogle Scholar
  4. 4.
    Ross R, Vogel A (1978) The platelet-derived growth factor: a review. Cell 14: 203PubMedCrossRefGoogle Scholar
  5. 5.
    Witte LD, Cornicelli JA, Miller RW, Goodman DS (1984) Effects of platelet-derived and endothelial cell-derived growth factors on the low density lipoprotein receptor pathway in cultured human fibroblasts. J Biol Chem 257: 5392Google Scholar
  6. 6.
    Denel RF, Senior RM, Huang JS, Griffin GL (1982) Chemotaxic of monocytes and neutrophils to platelet-derived growth factor. J Clin Invest 69: 1046CrossRefGoogle Scholar
  7. 7.
    Tzeng DY, Denel RF, Huang JS, Baehner RL (1985) Platelet-derived growth factor promotes human peripheral monocyte activation. Blood 66: 179PubMedGoogle Scholar
  8. 8.
    Lewy RI, Smith JB, Silver JB, Saia J, Walinsky P, Wiener L (1979) Detection of thromboxane B2 in peripheral blood of patients with Prinzmetals angina. Prostaglandins Med 2: 243PubMedCrossRefGoogle Scholar
  9. 9.
    Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT (1981) Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 304: 685PubMedCrossRefGoogle Scholar
  10. 10.
    Fitzgerald GA, Pedersen AK, Patrono C (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67: 1174PubMedCrossRefGoogle Scholar
  11. 11.
    Pitt B, Stea MJ, Romson JL, Lucchesi BR (1983) Prostaglandins and prostaglandin inhibitors in ischemic heart disease. Ann Intern Med 99: 83PubMedGoogle Scholar
  12. 12.
    Sinzinger H, Silberbauer K, Geigl W, Wagner O, Winter M, Auerswald W (1979) Prostacyclin activity is diminished in different types of morphologically controlled human atherosclerotic lesions. Thromb. Haemost 42: 803PubMedGoogle Scholar
  13. 13.
    Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA (1986) Platelet activation in unstable coronary disease. N Engl J Med 315: 983PubMedCrossRefGoogle Scholar
  14. 14.
    Flower RJ, Blackwell GJ (1976) Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 278: 456.CrossRefGoogle Scholar
  15. 15.
    Jorgensen KA, Stofferson E (1981) Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production. Pharmacol Res Commun 13: 579PubMedCrossRefGoogle Scholar
  16. 16.
    Blajchman, MA, Senyi AF, Hirsh J (1979) Shortening of the bleeding time in rabbits by hydrocortisone caused inhibition of prostacyclin generation by the vessel wall. J Clin Invest 63: 1026PubMedCrossRefGoogle Scholar
  17. 17.
    Roth GJ, Siok CJ (1978) Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 253: 3782PubMedGoogle Scholar
  18. 18.
    Parett FI, Mannucci PM, D’Angelo A, Smith JB, Santebin L, Galli G (1980) Congenital deficiency of thromboxane and prostacyclin. Lancet I: 898CrossRefGoogle Scholar
  19. 19.
    Bertele V, Salzman, EW (1985) Antithrombotic therapy in coronary artery disease. Artherosclerosis 5: 119Google Scholar
  20. 20.
    Lewis HD, David JW, Archibald DG, Steinke, WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, PougetJM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309: 396PubMedCrossRefGoogle Scholar
  21. 21.
    Cairns J, Gent M, Singer J, Finnie K, Froggat G, Holder D, Jablonsky G, Kostuk W, Melendez L, Myers M, Sackett D, Sealey B, Tanser P (1984) A study of aspirin and/or aulfinpyrazone in unstable angina. Circulation 70: 415Google Scholar
  22. 22.
    Fuster, V., Chesebro, JH (1986) Mechanisms of unstable angina. N Engl J Med 315: 1023.PubMedCrossRefGoogle Scholar
  23. 23.
    Rybicki JP, LeBreton GC (1983) Prostaglandin H2 directly lowers human platelet cAMP levels. Thromb Res 30: 407PubMedCrossRefGoogle Scholar
  24. 24.
    Malmsten C, Hamberg M, Svensson J, Samuelsson B (1975) Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclooxygenase deficiency. Proc Natl Acad Sci USA 72: 1446PubMedCrossRefGoogle Scholar
  25. 25.
    Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, Tack-Goldman K, Gay WA (1983) Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 308: 800PubMedCrossRefGoogle Scholar
  26. 26.
    Hanley SP, Bevan J (1985) Inhibition by aspirin of human arterial and venous prostacyclin synthesis. Prostaglandins Leukotrienes Med 20: 141CrossRefGoogle Scholar
  27. 27.
    Lorenz RL, Schacky CV, Weber M, Meister W, Kotzur J, Reichardt B, Theisen K, Weber PC (1984) Improved aorto coronary bypass patency by low dose aspirin (100 mg daily). Effect on platelet aggregation and thromboxane formation. Lancet I: 1261CrossRefGoogle Scholar
  28. 28.
    Miwa K, Kambara H, Kawai C (1981) Exercise-induced angina provoked by aspirin administration in patients with variant angina. Am J Cardiol 47: 1210PubMedCrossRefGoogle Scholar
  29. 29.
    Goetzl EJ, Hill HR, Gorman RR (1980) Unique aspects of the modulation of human neutrophils function by 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid. Prostaglandins 19: 71PubMedCrossRefGoogle Scholar
  30. 30.
    Gerrity RG (1981) Transition of blood borne monocytes into foam cells in fatty lesions. AM J Pathol 103: 181PubMedGoogle Scholar
  31. 31.
    Bertele V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, de Gaetano G (1984) Pharmacological inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products. Blood 63: 1460PubMedGoogle Scholar
  32. 32.
    Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry J (1980) Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb. Res. 20: 219PubMedCrossRefGoogle Scholar
  33. 33.
    Schafer AI, Crawford DD, Gibrons MI (1984) Unidirectional transfer of prostaglandin endoperoxides between platelet and endothelial cells. J Clin Invest 73: 1105PubMedCrossRefGoogle Scholar
  34. 34.
    Vermylen J, Defreyn G, Carreras LO, Machin SJ, Van Schoeren J, Verstraete M (1981) Thromboxane synthetase inhibition as antithrombotic strategy. Lancet I: 1073CrossRefGoogle Scholar
  35. 35.
    Riess H, Hiller E, Reinhardt B, Bräuning C (1984) Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease. Thromb Res 35: 371PubMedCrossRefGoogle Scholar
  36. 36.
    Riess H, Höfling B, Von Arnim T, Hiller E (1986) Thromboxane receptor blockade versus cyclooxygenase inhibition: antiplatelet effects in patients. Thromb Res 42: 235PubMedCrossRefGoogle Scholar
  37. 37.
    Sinzinger H (1983) Pentoxifylline enhances formation of prostacyclin from rat vascular and renal tissue. Prostaglandin Leukotrienes Med 12: 217CrossRefGoogle Scholar
  38. 38.
    Slany J, Silberbauer K, Sinzinger H, Panzergruber CH (1981) Einfluß von Molsidomin auf die Thrombozytenaggregation and das Prostaglandinsystem. Zschr Kardiol 70: 269Google Scholar
  39. 39.
    Chamone DAF, Vermylen J, Verstraete M (1979) Bay g6575, an antithrombotic compound that stimulates prostacyclin release from the vessel wall. Thromb Haemost 42: 369Google Scholar
  40. 40.
    Moncada S, Vane JR (1979) Arachidonic acid metabolites and the interaction between platelets and blood vessel walls. N Engl J Med 300: 1142PubMedCrossRefGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1986

Authors and Affiliations

  • H. Riess
    • 1
  1. 1.Medizinische Klinik IKlinikum Großhadern der Universität MünchenMünchen 70Germany

Personalised recommendations